Clinical trial
ACP-103 to Treat Parkinson's Disease
NCT00086294 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00086294 |
|---|---|
| Title | ACP-103 to Treat Parkinson's Disease |
| Official title | 5HT2A/C Serotonin Blockade in Parkinson's Disease |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease, Dyskinesias |
| Intervention type | Drug |
| Interventions | Intravenous Levodopa, ACP-103 |
| Enrollment | 40 |
| Start date | Jun 25, 2004 |
| Completion | Nov 15, 2007 |
| First posted | Jun 30, 2004 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: